For example, JAK/STAT3 inhibitors are under development and have shown early promise in gastric cancer patients [27,39,40,41,42,43], and FOXM1 inhibitors or cell cycle modulators could potentially be explored to specifically curb the proliferative drive in PGC [43,44,45]. Here, STAT3 is linked to gastric cancer.